HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Iovance Biotherapeutics, Inc.

Contributing Author

Recent Articles by Iovance Biotherapeutics, Inc.

Mar-20
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Feb-26
Iovance Biotherapeutics to Present at Upcoming Conferences IOVA GlobeNewswire
Feb-24
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas IOVA +30.80% GlobeNewswire
Feb-24
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates IOVA +30.80% GlobeNewswire
Feb-20
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA GlobeNewswire
Feb-11
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 IOVA GlobeNewswire
Feb-05
Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma IOVA +7.20% IOVA GlobeNewswire
Jan-16
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +6.31% GlobeNewswire
Dec-19
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +12.10% IOVA GlobeNewswire
Nov-21
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +11.61% IOVA GlobeNewswire
Nov-06
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results IOVA +27.62% GlobeNewswire
Nov-03
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) IOVA GlobeNewswire
Oct-23
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025 IOVA GlobeNewswire
Oct-17
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +6.42% IOVA GlobeNewswire
Sep-19
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA -6.82% GlobeNewswire
Aug-29
Iovance Biotherapeutics to Present at Upcoming Conferences IOVA GlobeNewswire
Aug-22
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA -5.95% IOVA +5.91% GlobeNewswire
Aug-18
Iovance's Amtagvi (lifileucel) Receives Health Canada Approval for Advanced Melanoma IOVA GlobeNewswire
Aug-07
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 IOVA -20.08% IOVA GlobeNewswire
Jul-24
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025 IOVA -17.13% GlobeNewswire
Jul-18
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +11.66% IOVA GlobeNewswire
Jul-15
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer IOVA GlobeNewswire
Jul-14
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi in Patients with Advanced Melanoma IOVA +7.49% GlobeNewswire
Jul-10
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy IOVA GlobeNewswire
Jun-23
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA -6.57% GlobeNewswire
Jun-10
Iovance Biotherapeutics to Present at Upcoming Conference IOVA +7.69% GlobeNewswire
Jun-02
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi (lifileucel) in Patients with Advanced Melanoma IOVA GlobeNewswire
May-22
Iovance Announces Five-year Results of Amtagvi (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting IOVA GlobeNewswire
May-16
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) IOVA +10.24% IOVA -5.68% GlobeNewswire
May-08
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 IOVA -44.79% IOVA GlobeNewswire
May-02
Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025 IOVA +5.11% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)